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Abstract: 
Objectives: Hypophosphataemic rickets (HR) is usually secondary to renal phosphate 
wasting but may occur secondary to reduced intake or absorption of phosphate. We describe 
a series of cases of HR associated with the use of Neocate®, an amino-acid based formula 
(AAF). 
Methods: A retrospective review of cases with HR associated with AAF use presenting to 
centres across the United Kingdom.  
Results: 10 cases were identified, over a 9 month period, all associated with Neocate® use. 
The age at presentation was 5 months to 3 years. The majority (8/10) were born prematurely. 
Gastro oesophageal reflux disease (6/10) was the most frequent indication for AAF use. 
Radiologically apparent rickets was observed after a median of 8 months (range 3-15 months) 
of exclusive Neocate® feed. The majority (7/10) were diagnosed on the basis of incidental 
findings on radiographs: rickets (6/10) or fracture with osteopenia (5/10). All patients had 
typical biochemical features of HR with low serum phosphate, high alkaline phosphatase, 
normal serum calcium and 25 hydroxyvitamin D. However, in all cases the tubular 
reabsorption of phosphate (TRP) was ≥ 96%. Phosphate supplementation resulted in 
normalisation of serum phosphate within 1 to 16 weeks, and levels remained normal only 
after Neocate® cessation. In patients with sufficient follow up duration (4/10), normalisation 
of phosphate and radiological healing of rickets was noted after 6 months (range: 6- 8 
months) following discontinuation of Neocate®.  
Conclusion: The presence of a normal TRP and resolution of hypophosphataemia and rickets 
following discontinuation of Neocate® indicates this is a reversible cause likely mediated by 
poor phosphate absorption. Close biochemical surveillance is recommended for children on 
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Neocate®, especially in those with gastrointestinal co-morbidities, with consideration of a 
change in feed or phosphate supplementation in affected children.  
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Introduction:  
Rickets is caused by defective mineralisation at the growth plate. Rickets is often classified as 
calcipaenic or phosphopaenic depending on whether the primary cause is a shortage of 
calcium or phosphate. However, the underlying mechanism of all forms of rickets is low 
phosphate availability at the growth plate preventing apoptosis of hypertrophic chondrocytes 
and reduced mineralisation of newly formed bone matrix [1]. The leading cause of nutritional 
rickets worldwide is vitamin D deficiency [2]. Hypophosphataemic rickets (HR) in children 
usually has an underlying genetic basis [3], but HR may also occur from chronic 
hypophosphataemia secondary to reduced phosphate availability from poor oral intake or 
malabsorption or renal phosphate leak. Dietary phosphate deficiency is now a rare entity 
having previously been seen in premature babies who were exclusively breast milk fed [4]. 
Poor gastrointestinal phosphate absorption can occur in the setting of prematurity, vitamin D 
deficiency and use of phosphate binders [5]. Increased renal phosphate loss occurs in primary 
or secondary hyperparathyroidism, vitamin D deficiency and renal tubular disorders such as 
Lowe’s syndrome, Dent’s disease, congenital or acquired Fanconi’s syndrome [6]. 
 
Renal phosphate wasting is associated with low tubular reabsorption of phosphate (TRP) 
whereas low serum phosphate from dietary deficiency or malabsorption is associated with a 
normal or high TRP.  Recently, the use of elemental formula was implicated in the 
development of HR [7]. Here, we describe a series of cases from across the United Kingdom 
with a rare cause of hypophosphataemia and HR related to the use of an amino acid based 
formula (AAF), Neocate®.  
Methods:  
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A retrospective review of case notes was undertaken of children with hypophosphataemia and 
HR, whilst consuming Neocate®, a specific AAF, from various centres across the United 
Kingdom. Following description of the first case of Neocate® associated HR in the UK in 
2016 [8] an effort was made to identify similar cases through the British Paediatric and 
Adolescent Bone Group and the British Society of Paediatric Endocrinology and Diabetes 
monthly newsletter between February and April 2017. When a potential case was identified, a 
standard proforma was used to collect further details to characterise the pre-disposing factors, 
clinical and biochemical features, response to various management strategies and outcome.  
Patients and results:  
A total of 10 cases from 6 centres across the UK were collated between November 2016 and 
July 2017. All cases were associated with use of the AAF, Neocate®. Biochemical 
surveillance had not been instituted in any of the cases prior to presentation. Table 1 provides 
details of Neocate® feed and treatment and Table 2 the biochemical features at presentation.   
 
Clinical details at presentation: 
Patient 1: Six month old male infant (born 31+0 weeks gestation) with presumed cow’s milk 
protein allergy (CMPA) was incidentally found to have rickets on a chest radiograph 
performed during an admission for bronchiolitis.  
Patient 2: Ten month old female infant (born 27+0 weeks gestation) with gastro-oesophageal 
reflux disease (GORD) and CMPA was referred with bowing deformities of the legs.  
Patient 3: Eleven month old male infant (born 33+6 weeks gestation) with Pierre-Robin 
sequence, cleft palate and GORD was referred for incidental finding of rickets on a chest 
radiograph. He had undergone fundoplication for severe GORD.  
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Patient 4: Eighteen month old female child (born at term) with CHARGE association and 
GORD was referred for incidental finding of rickets on chest radiographs.  
Patient 5: Nine month old male infant (born 31+0 weeks) with chronic lung disease, severe 
bronchiolitis warranting tracheostomy, GORD and failure to thrive was referred for oblique 
fracture of the right femur and rachitic changes on chest radiograph.  
Patient 6: A 3 year old female child (born at term) with severe combined immune-deficiency 
was referred for fracture of the femur and osteopenic bones on radiographs. She was 
receiving steroids for severe graft versus host disease following bone marrow transplantation.  
Patient 7: Five month old male infant (born 34+4 weeks gestation) with septo-optic dysplasia, 
GORD, chromosome 8q12.3 deletion and tectal plate glioma was incidentally found to have 
low serum phosphate and high alkaline phosphatase (ALP) on surveillance. 
Patient 8: Nine month old female infant (born 34+3 weeks gestation) with CMPA and GORD 
was referred for multiple fractures and rickets on radiographs.   
Patient 9: Eight month old male infant (born 28+0 weeks) with microcephaly, hypoxic 
ischaemic brain injury, previous E-coli sepsis and meningitis, poor growth, disordered 
development and possible cortical blindness was referred due to an incidental finding of 7th 
rib fracture and osteopenia on chest radiograph.   
Patient 10: Fifteen month old female infant (born 25+4 weeks gestation) with evolving 
cerebral palsy, periventricular leucomalacia, short gut secondary to bowel resection, GORD, 
grade 2 retinopathy of prematurity, seizures and dystonia was monitored for ongoing 
hypophosphataemia and eventually sustained a fracture of the humerus, and rickets was noted 
on radiographs.   
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Clinical details following presentation: 
Hypophosphataemia was observed in all cases except patient 6 (P6) who was treated with 
phosphate supplements; P6 also had had a change in formula feed. Hypocalcaemia following 
phosphate supplementation occurred in three patients (P2, P4 and P9) necessitating calcium 
supplements and alfacalcidol treatment. Normalisation of serum phosphate, within 1 week to 
4 months, was noted in all 9 patients who received phosphate supplements. Patient 10 
experienced recurrent episodes of hypophosphataemia when off supplements.  
 
Patients who remained on exclusive Neocate® feed experienced disease progression with 
persistently elevated ALP, long bone deformities (P6), new fractures (P10) or recurrent 
fractures (P8 and P9) despite phosphate supplementation. Patient 4 who received other feeds 
in addition to Neocate® (50% total parenteral nutrition) experienced ongoing 
hypophosphataemia and raised ALP without disease progression. When Neocate® was 
stopped, either because it was suspected to have contributed to the hypophosphataemia or HR 
or changed as per dietetic plan (P3, P4); serum phosphate and ALP normalised. Radiological 
healing of rickets off Neocate® and phosphate supplements was noted in patients (P2, P3, P4 
and P8) where a minimum of 6 months follow up data was available. Figure 1 illustrates 
rickets on radiographs of patient 2 at presentation and healing at 6 months off supplements 
following Neocate® cessation.  
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Discussion:  
We highlight a rare and preventable cause of hypophosphataemia and HR in children related 
to the use of the AAF Neocate®. HR resulted in significant morbidity including skeletal 
deformity and fractures. We detail the associated co-morbidities, presenting features, 
biochemical characteristics, management and outcomes. There was a delay in suspecting 
Neocate® as the causative agent in the majority of the patients described, with some 
associations made only in retrospect, due to the lack of familiarity with this entity. 
A recent report of 51 cases from across 17 centres in the United States describes the 
association between the AAF Neocate® and hypophosphataemia in a large case series [7]. 
The findings from our cohort confirm that most cases are observed in children born 
prematurely and had other co-morbidities especially related to the gastro-intestinal system 
such as GORD.  The increased prevalence of hypophosphataemia and metabolic bone disease 
in preterm infants [9] can lead to a delay in considering Neocate® as the causative agent. One 
patient was noted to have hypophosphataemia shortly after commencing Neocate® but this 
was attributed to prematurity. After 4 months on Neocate®, osteopenia on radiographs was 
noted, which again was considered secondary to prematurity, and at 5 months on Neocate® 
presented with fractures.  
The absorption of minerals such as calcium and phosphate in preterm infants is reduced [4], 
hence pre-term formulae are enriched with minerals [10] to ensure adequate mineral supply 
for growing bones. The bioavailability of calcium and phosphorus from formula milk is less 
when compared to human milk [11]. Hypophosphataemia has not been associated with other 
amino acid (Nutramigen Puramino®) or extensively hydrolysed formulas (Infatrini peptisorb® 
and Nutramigen®), indicating its unique association with Neocate®. The Neocate® 
preparations available in the UK have changed over time. The current preparations include 
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Neocate® Syneo and LCP (Long Chain Polyunsaturated fatty acid) for infants and Neocate® 
junior for children aged >1 year, which was previously available as Neocate® advance. The 
phosphorous concentration in Neocate® LCP (341mg/100g) is relatively more when 
compared to other AAF such as Nutramigen Puramino® (260mg/100g) or other standard 
infant formulas such as SMA® PRO First Infant Milk (180 mg/100g). Although most patients 
in our cohort were on the Neocate® infant or LCP preparation, a similar association was noted 
in patients who were on Neocate® advance. 
The most common indication for Neocate® use in our cohort was GORD followed by cow’s 
milk protein intolerance (CMPI). Some patients were implicated to have co-existence of 
GORD and CMPA/CMPI. GORD is very common, affecting 40% of term infants [12] with a 
higher prevalence in premature infants which poses diagnostic and management challenges 
[13]. The reflux symptoms in GORD are often attributed to CMPA/CMPI and a trial of AAF 
is often initiated despite lack of diagnostic evidence [12]. The National Institute for Health 
and Care Excellence (NICE) guidelines discourage the use of AAF in GORD [12]. The 
European Society for Paediatric Gastroenterology, Hepatology And Nutrition (ESPGHAN) 
recommends a trial of extensively hydrolysed formula (eHF) before starting AAF for proven 
CMPA [14]. Extensively hydrolysed formulas are also reported to be more cost effective than 
AAF [15]. One patient was prescribed AAF by the general practitioner for presumed CMPA 
when presenting with reflux symptoms, which raises the question of whether patients should 
be reviewed by specialists before commencing AAF.  
Proton pump inhibitors (PPI) such as omeprazole and lansoprazole and H2 receptor 
antagonists (H2RA) such as ranitidine are frequently used in the setting of GORD, despite 
their use being discouraged [12]. The case series from the United States hypothesised that 
increased gastric pH secondary to antacid use or post-pyloric feed may contribute to altered 
calcium and phosphate absorption [7]. In our cohort, five patients received post-pyloric feeds, 
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however two were fed orally. Given that the phosphate content in Neocate® meets the 
recommended allowance [16] it is plausible to hypothesize altered absorption as the causative 
factor although the exact mechanism contributing to reduced absorption remains unclear.   
The clinical presentation included: incidental finding of rickets or fracture with osteopenia on 
radiographs, clinical presentation of fractures with rickets or osteopenia on radiographs, 
bowing deformity and biochemical abnormalities alone. One patient sustained a fracture 
(with rickets noted on radiographs) whilst under surveillance for hypophosphataemia.  
Only one patient was diagnosed early with biochemical features of HR (low phosphate and 
raised alkaline phosphatase with normal calcium and 25 hydroxyvitamin D). Despite the 
majority of the patients being under follow up in a secondary care centre with dietetic 
monitoring, the diagnosis was delayed. The duration of Neocate® feed prior to presentation in 
our cohort varied from a minimum of 3 months to a maximum of 15 months and we noted 
that the longer the duration of Neocate® use, the more severe the clinical manifestations were 
(rickets and recurrent fractures).  
Biochemical features at presentation were consistent in all patients with low serum 
phosphate, raised ALP and normal serum calcium (Table 2). Normal values for 25 hydroxy 
vitamin D and PTH excluded hyperparathyroidism and vitamin D deficiency. When renal 
TRP was calculated it was normal (≥96%) in all cases indicating normal renal tubular 
function. In the evaluation of patients with HR, in addition to a bone profile, PTH and serum 
25OHD levels, it is crucial to collect a paired urine and serum phosphate and creatinine to 
calculate the TRP. The TRP will be low in causes of renal phosphate wasting but normal or 
high in Neocate® associated HR. The paired samples must be collected before starting any 
phosphate supplements as this will help distinguish renal phosphate wasting (reduced TRP) 
from nutritional insufficiency (normal or increased TRP). The manufacturers highlight the 
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need for biochemical monitoring (6 months after starting Neocate® and then annually or more 
frequently if required) for micronutrient deficiencies in children with co-morbidities. Based 
on our experience with the above cohort, as a minimum we recommend monitoring serum 
phosphate and ALP monthly. Currently there is lack of robust evidence to recommend routine 
monitoring in well children on Neocate® in the community. Although a recent study has 
reported normal mineral status in well children with CMPA on amino acid based formula 
Neocate® [17], the study was limited due to its very short duration of follow up (16 weeks) 
and lack of bone turnover markers (ALP) for identification of early bone disease.  
Primary treatment included phosphate supplementation as with management of any other 
form of HR [18] apart from one patient who received a change in formula as an association 
between AAF feed and hypophosphataemia was recognised at an early stage. Hypocalcaemia 
following phosphate supplementation was noted in three patients necessitating calcium 
supplementation and/or alfacalcidol treatment. We therefore recommend close monitoring of 
serum calcium at treatment initiation and encourage the use of alfacalcidol to maximise 
calcium absorption. Ultimately, all except one patient had a change in formula either due to 
ongoing hypophosphataemia or as per dietetic plan. Reversal of biochemical and radiological 
signs of rickets was noted in patients off Neocate® and off phosphate supplements with 
sufficient follow up duration indicating a reversible cause of hypophosphataemia.  
Our study is limited due to its retrospective nature. The association of AFF and HR was made 
in retrospect in two patients. It is difficult to identify definitive risk factors due to the 
complex medical background of the majority of the children reported here. It is not known 
whether well children in the community on Neocate® for prolonged duration (> 3 months) 
have biochemical or radiological abnormalities, which warrants further prospective studies.
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It is likely that Neocate® associated hypophosphataemia is due to poor intestinal absorption 
of phosphate, which is also supported by reversal of hypophosphataemia following 
discontinuation of this formula. Healthcare professionals diagnosing and managing GORD 
and CMPA/ CMPI should be familiar with practice guidelines, the association of AAF 
Neocate® with hypophosphataemia, and adopt close monitoring of children with 
gastrointestinal co-morbidities as per the manufacturer’s recommendations.  Management of 
Neocate® associated hypophosphataemia should include change of formula where feasible 
and phosphate supplementation where necessary.  
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Figure 1: Radiographs of patient 2 demonstrating radiological evidence of rickets at 
diagnosis (a & b) and healing of rickets 6 months (c & d) after stopping Neocate®.  
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Table 1: Feed specifications and indications; and treatment on all patients are detailed below. Abbreviations used are indicated below the table.  
 
 
LCP= Long Chain Polyunsaturated fatty acid, CMPA= Cow’s milk protein allergy, GORD= Gastro oesophageal reflux disease, CMPI= Cow’s milk protein 
intolerance, NJ= Naso-jejunal, NG= Nasogastric, ALP= Alkaline phosphatase 
 Patient 1  Patient 2  Patient 3  Patient 4  Patient 5  Patient 6  Patient 7  Patient 8  Patient 9 
 
Patient 10 
Presentation 
age (months) 
6 10 11 18 9 36 5 9 8 15 
Type of   
formula  
Neocate®         
LCP 
Neocate® LCP Neocate® LCP 17%  
Neocate® LCP 
20.7%  
Neocate® LCP  
Neocate® LCP 
then Neocate®  
advance 
Neocate® LCP Neocate® 
LCP 
Neocate® 
LCP 
Neocate® 
LCP+ junior 
Neocate® 
indication 
Presumed 
CMPA 
GORD, CMPI Severe 
GORD, 
lactose 
intolerance 
GORD GORD, failure 
to thrive, family 
history of 
CMPA 
Refusing feed,  
milk, egg, 
wheat, soy free 
diet 
Severe 
GORD. 
Suspected 
CMPA 
CMPI CMPI Short gut, 
GORD 
Route of Feed Oral Oral NJ and then 
gastrostomy  
Gastrostomy NG and then NJ 
via gastrostomy 
NG and oral  NJ Gastrostomy NG and 
then NJ 
NJ 
Exclusive  
Neocate® pre 
diagnosis  
3 months 10months 8months  >6 months 5 months 15 months 5 months 7.5 months 8 months 11 months 
Antacid use No Yes  
Lansoprasole 
Yes  
Omeprazole 
 
Yes 
Lansoprazole  
No Yes   
Lansoprasole 
Yes 
Lansoprasole 
Yes 
Omeprazole 
Ranitidine 
Yes 
Ranitidine 
Yes 
Omeprazole 
Neocate® 
stopped as part 
of treatment 
Yes Yes No No  Yes Yes Yes Yes Yes No 
Phosphate 
supplements 
Yes, 2 
months 
Yes, 3 months Yes, 14m  
 
6 days; 
stopped as 
hypocalcaemic  
Yes Yes No Yes, 6 
months  
Yes Yes, on and 
off for 1 
year 
Additional 
treatment  
Alfacalcidol 
and  
Vitamin  D3 
Calcium 
supplements 
Vitamin D3 Vitamin D3 
and  
Calcium 
supplements 
 Bisphosphonate 
(x1 infusion)  
  Alfacalcid
ol and  
Calcium 
supplemen
ts 
Calcium 
supplements 
and Vitamin 
D3 
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Table 2: Biochemical features at presentation  
 Patient 1 Patient 2  Patient 3  Patient 4 Patient 5  Patient 6  Patient 7  Patient 8  Patient 9 
 
Patient 10 
Serum calcium mmol/L 
NR 2.2-2.7 
2.46 2.52 2.6 2.28 2.57 2.47 2.38 2.51 2.21 1.89 
Serum phosphate mmol/L 
NR 1.3-2.4 
1.23 0.68 0.83 1.04 0.84 1.34 0.63 0.7 1.04 0.6 
Alkaline phosphatase IU/L 
NR 105-420 
1000 1000 3469 431 1653 419 2206 906 2241 1024 
Parathyroid hormone   
NR 10-65 ng/L  
24 19.8 17 54 21 31 Normal 9 14 
 
16.5 
25 hydroxy vitaminD 
nmol/L NR >50 
59.7 86 88 347 76 131 110 73  106 33 
1,25 dihydroxy vitamin D 
pmol/L NR 20-120 
>250 - >250 - - - - 454  336 - 
Tubular reabsorption of 
phosphate    
NR >80% 
99.7% - 99.8% 97% 
 
- - - 96% 96% 96% 
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